The DISCUS trial comparing 3 vs 6 cycles of chemo followed by maintenance Avelumab has over 100 patients 🇬🇧 🇪🇸 🇫🇷 Enrique Grande Yohann Loriot drfrankiejs Is 6 cycles too much and ⬇️ effect on QOL? Will IO work better after 3. Novel ctDNA and wearable device endpoints,

A huge step for bladder cancer! Exciting to have worked on this trial!

A monumental moment for bladder cancer today. A privilege to have worked on this trial which will change the landscape of bladder cancer. 👏🏻

Hit the poster sessions in Hall 8 to see the stars of yesterdays presidential session (#EV302 Tom Powles & #CM901 Michiel van der Heijden) presenting work w their mentees (drfrankiejs & Chantal Stockem)! So many stars out at this #ESMO23 session, incl Renee Maria Saliby Dana-Farber Lank Center for Genitourinary Oncology &

Our Clinical Research Fellows Dr Bernadett Szabados, Dr Matthew Young and Dr Francesca Jackson-Spence presenting data at #ASCOGU24 this week in San Francisco. Great work from the GU oncology team led by Prof Tom Powles Tom Powles

Dear Colleagues at #GU24 An honor to introduce our colleague drfrankiejs 🇬🇧 Discussing: "Top advances of the year: Genitourinary cancer" Free Download Link: acsjournals.onlinelibrary.wiley.com/doi/full/10.10… written by drfrankiejs along with our OncoAlert 🚨faculty Tom Powles 🇬🇧 Barts Cancer Institute (Queen Mary) and

Featured in OncoAlert: Hear about past-year top advances in #GUCancer from Dr. Francesca Jackson-Spence drfrankiejs. Her commentary written with Barts Experimental Cancer Medicine Centre investigators discusses some of the most compelling published data that could change the treatment landscape. #GU24

Our poster from Barts Experimental Cancer Medicine Centre on survivorship issues in #testicularcancer now up in #GU24. We highlight the nature & incidence of long-term issues following orchidectomy and/or chemotherapy, underscoring importance of eliciting and addressing these issues in our f/u clinics.

Dr Francesca Jackson-Spence presenting her work at ASCO #GU24 investigating baseline characteristics associated with ineligibility to receive avelumab maintenance therapy in frontline bladder cancer. drfrankiejs Barts Experimental Cancer Medicine Centre

Championing the importance of Patient and Public Engagement and Involvement in cancer research and trials. Today Barts Experimental Cancer Medicine Centre PPIE group are visiting Cambridge ECMC to collaborate on PPIE initiatives. The start of a great partnership within the ECMC Network (@ecmc-uk.bsky.social) network!

Just in Kidney Cancer 👉Excellent review by drfrankiejs Tom Powles on adjuvant Rx in RCC #kidneycancer 👉w/ the +ve results of KEYNOTE-564, biomarkers are needed to identify pts who may benefit from adj Rx👇👇 tinyurl.com/y6w52prn Uromigos OncoAlert KidneyCAN Kidney Cancer

⚡️Extended OS in #KidneyCancer pts normalising their #NLR by week 12 reveals noteworthy insights. Dynamic biomarkers may outperform baseline scores during the ICIs era. Exciting collaboration with #MattYoung , Bernadett Szabados , drfrankiejs, and Prof Tom Powles at Barts Experimental Cancer Medicine Centre.

The DISCUS trial (3 vs 6 cycles of chemo then avelumab) needs 50 more pts for its initial readout. An investigator led study in 🇬🇧 🇫🇷 🇪🇸 Enrique Grande Yohann Loriot with novel endpoints (ctDNA/wearable devices etc).Will cropping chemo help?Will 3 cycles have a role if +ve? #ASCO24

SAMETA: the 1st biomarker driven R3 papillary RCC study #GU25 . CALYPSO is the phase 2 data supporting it. RR PFS and OS in the MET driven group looks promising for durva/savolitinib. drfrankiejs also presents baseline and dynamic ctDNA analysis. A new biomarker in PRCC?

Great Renal cancer rapid oral session Toni Choueiri, MD drfrankiejs - will durvalumab + savolitinib beat sunitinib in papillary RCC ? SAMETA will tell us . Barts Experimental Cancer Medicine Centre

Dr Francesca Jackson-Spence, PhD candidate at Barts Experimental Cancer Medicine Centre presents final survival data and a novel ctDNA analysis from the Barts Cancer Institute (Queen Mary) led phase II CALYPSO trial at ASCO #GU25 looking at targeting MET in advanced papillary renal cancer drfrankiejs

Final survival data and ctDNA data from the CALYPSO trial presented by Dr Francesca Jackson-Spence at ASCO #GU25 - RR and OS are enhanced in MET-driven papillary RCC. ctDNA at baseline is prognostic. CtDNA may be a useful tool in papRCC Barts Cancer Institute (Queen Mary) Tom Powles UroToday.com drfrankiejs

Watch my UroToday.com interview summarising the papillary CALYPSO trial final survival data and ctDNA analysis. Originally presented at ASCO #GU25 urotoday.com/video-lectures…

#CALYPSO trial: Savolitinib and durvalumab in advanced papillary #RenalCancer. Francesca Jackson-Spence Barts Experimental Cancer Medicine Centre joins Pedro C Barata, MD MSc FACP Case Comp Cancer Ctr to discuss final overall survival data and circulating tumor DNA analysis for patients with advanced papillary renal cancer in the CALYPSO

#CALYPSO trial: Savolitinib and durvalumab in advanced papillary #RenalCancer. Francesca Jackson-Spence Barts Experimental Cancer Medicine Centre joins Pedro C Barata, MD MSc FACP Case Comp Cancer Ctr to discuss final overall survival data and circulating tumor DNA analysis for patients with advanced papillary renal cancer in the CALYPSO